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Abstract 
Background: Evodiamine has gained wide interests recently because of its antitumor activities. However, a supe‑
rior bioavailability is required to achieve better efficacy due to its poor water solubility. The aim of this study was to 
enhance the evodiamine’s aqueous solubility by preparing evodiamine/hydroxypropyl‑β‑cyclodextrin (EVO/HP‑β‑CD) 
inclusion complex, which is incorporated evodiamine into HP‑β‑CD, and compare the antitumor activities before and 
after inclusion with HP‑β‑CD in human hepatoma HepG2 cells.
Results: The EVO/HP‑β‑CD inclusion complexes were prepared by the kneading method and structurally charac‑
terized. P‑glycoprotein ATPase assays firstly demonstrated that evodiamine was a substrate of P‑glycoprotein, while 
HP‑β‑CD and EVO/HP‑β‑CD inclusion complexes inhibited P‑glycoprotein by blocking P‑glycoprotein ATPase activ‑
ity. The EVO/HP‑β‑CD inclusion complexes may be a promising anticancer drug candidate without drug resistance. 
After given evodiamine or EVO/HP‑β‑CD inclusion complexes intervention, cell viability evaluation indicated that the 
half inhibition concentration of evodiamine and EVO/HP‑β‑CD inclusion complexes on HepG2 cells was 8.516 and 
0.977 μM, respectively. The caspase‑3 enzyme activity analysis and Annexin V/PI double‑staining revealed that EVO/
HP‑β‑CD inclusion complexes possessed better antitumor activities than evodiamine. Additionally, Hoechst 33258 
staining and terminal deoxynucleotidyl transferase‑mediated dUTP nick‑end labelling assay demonstrated that EVO/
HP‑β‑CD inclusion complexes induced HepG2 cell apoptosis more effectively than evodiamine.
Conclusions: The improved antitumor activities of evodiamine were attributed to the enhanced solubility and 
P‑glycoprotein inhibition by HP‑β‑CD. These results are promising for the drug administration of EVO/HP‑β‑CD inclu‑
sion complexes to enhance the bioavailability of evodiamine in vivo.
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Background
Evodiamine (Fig.  1A), a quinolone alkaloid, is a major 
bioactive component extracted from the fruit of Evo-
diarutaecarpa (Juss.) Benth. It participates in diverse 
pharmacological bioactivities, such as antiobesity [1, 2], 
anti-cancer [3–5], and analgesic activities [6]. It plays a 
role in regulating the expression of the serotonin trans-
porter [7], improving cognitive abilities in transgenic 
mouse models of Alzheimer’s disease [8], and stimulating 
catecholamine secretion [9]. However, its poor water sol-
ubility hampers its application in pharmaceutical fields. 
Therefore, it is necessary to increase its aqueous solubil-
ity to improve its pharmaceutical properties. In recent 
years, several studies have been devoted to the develop-
ment of novel evodiamine formulations to improve its 
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bioavailability, including phospholipid complexes [10] 
and microemulsions [11, 12].
Cyclodextrins (CDs), which are cyclic oligosaccharides 
in the shape of truncated cones, fascinate many scientists 
because of their hydrophilic outer surfaces and somewhat 
hydrophobic central cavity. CDs can form water-soluble 
inclusion complexes with various poorly water-soluble 
compounds, thereby enhancing the bioavailability of 
insoluble drugs by increasing the drug solubility, dis-
solution, and/or drug permeability [13–15]. It has been 
reported that CDs or their chemically modified deriva-
tives can improve water solubility and the bioavailability 
of drugs with poor water solubilities [16, 17]. The most 
commonly used CDs are β-cyclodextrin (β-CD) and its 
chemically modified derivatives, such as hydroxypropyl-
β-cyclodextrin (HP-β-CD) and sulfobutylether-β-CD. 
HP-β-CD has been widely acknowledged for its increased 
water-solubility, lower toxicity, and higher inclusion abil-
ity relative to natural β-CD. It is also known that cancer 
drug resistance develops because of the presence of mul-
tidrug resistance (MDR) genes in cancer cell membranes 
[18–20]. P-glycoprotein (Pgp), encoded by MDR1 which 
is the first human ATP-binding cassette (ABC) trans-
porter gene, influences drug absorption, distribution, 
and secretion. Consequently, it is very important to iden-
tify a Pgp inhibitor with few side effects to improve drug 
absorption in cancer treatments. It has been reported 
that HP-β-CD inhibits Pgp by blocking Pgp ATPase 
activity, which could enhance drug absorption [11, 21].
At present, no aqueous formulation of evodiamine 
is available. In this investigation, evodiamine inclusion 
complexes were prepared with HP-β-CD to improve the 
water solubility of evodiamine. Then, the antitumor activ-
ities of EVO/HP-β-CD and evodiamine were compara-
tively studied by measuring caspase activities, Hoechst 
staining, and TUNEL assays. A Pgp ATPase assay was 
also used to identify whether HP-β-CD acted as a Pgp 
inhibitor and whether evodiamine was a Pgp substrate.
Methods
Materials
Evodiamine (purity  >98  %) was purchased from Nan-
jing Goren Bio-Technology Co., Ltd. (Nanjing, China). 
HP-β-CD (CAVASOL®HP, molecular mass 1540) was pur-
chased from Wacker Chemie AG (Munich, Germany). 3-(4, 
5- dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide 
(MTT) and Dulbecco’s modified Eagle’s medium (DMEM, 
high glucose) were purchased from Sigma-Aldrich (St 
Louis, MO, USA). Double distilled water was obtained 
from a Milli-Q water purification system (Merck Millipore, 
Bedford, MA, USA). The Annexin V apoptosis detection 
kit (FITC) was purchased from eBioscience (San Diego, 
CA, USA). Bisbenzimide H 33258 (Hoechst 33258) was 
obtained from Sigma-Aldrich (St Louis, MO, USA).
Cell culture and drug treatments
The human hepatoblastoma cell line HepG2 was pur-
chased from the Cell Culture Center of the Chinese 
Academy of Sciences (Shanghai, China) and cultured in 
DMEM with 10 % foetal bovine serum at 37 °C in a 5 % 
CO2 humidity incubator for 24 h. Then, varying concen-
trations of evodiamine or equimolar concentrations of 
EVO/HP-β-CD or HP-β-CD were added to the culture 
plates. Cells at 80–90  % confluence were used for all of 
the experiments.
Phase solubility studies
Phase solubility studies were adapted from a method 
introduced by Higuchi and Connors et  al. [22]. An 
excess amount of evodiamine (10 mg) was added to 3 mL 
Fig. 1 The chemical structures and labelled protons of A evodiamine and B HP‑β‑CD
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deionized water with various concentrations of HP-β-CD 
(0–400  mM) in 20  mL glass vials. The suspension solu-
tion was agitated on an IKA® RO10 magnetic stirrer 
(IKA, Germany) at 800  rpm and room temperature 
(25 °C) for 24 h and then filtered through a 0.45 μm pore 
size PES syringe filter (Millipore, USA) to obtain a clear 
solution, which was then assayed by high-performance 
liquid chromatography (HPLC). The assay was per-
formed on a Waters 515 HPLC pump and a Waters 2695 
system equipped with a Waters 2487 dual wavelength 
absorbance detector at 225 nm. Ten microliters of sample 
was injected into a Kromasil C18 column (4.6 × 250 mm, 
Eka Chemicals AB, Sweden). The mobile phase consisted 
of acetonitrile/water (70:30, v/v) containing 0.05 % (v/v) 
triethylamine and 0.1  % (v/v) phosphoric acid at a flow 
rate of 1.0 mL/min. All of the test groups were performed 
in triplicate. The phase solubility curve was obtained by 
plotting the concentration of the dissolved drug versus 
the concentration of HP-β-CD.
Preparation of evodiamine inclusion complexes 
with HP‑β‑CD
The inclusion complexes were prepared by the knead-
ing method combined with a stirring method at a molar 
ratio of 2:1 (HP-β-CD:evodiamine). HP-β-CD was accu-
rately weighed and transferred to a mortar. Subsequently, 
a small amount of water was added, and the mortar 
contents were kneaded until a homogeneous paste was 
obtained. Then, an appropriate amount of evodiamine 
dispersed in a small amount of ethanol/tetrahydrofuran 
(2:1, v/v) was added to this paste, and the mixture was 
continuously kneaded for 45  min at room temperature. 
Next, the paste was transferred into a round flask con-
taining 50 mL of ethanol. The suspension was stirred at 
800 rpm for 24 h at 45 °C. The solution was then filtered 
with a 0.45 μm pore size nylon membrane syringe filter 
(Millipore, USA). The solution supernatant was recov-
ered and concentrated, and then the residue was dried in 
an oven at 45 °C.
Physicochemical characterization of the samples
Differential scanning calorimetry (DSC)
Thermodynamic analyses were performed on a DSC7 dif-
ferential scanning calorimeter (Perkin-Elmer, Norwalk, 
CT, USA). Evodiamine, the physical mixture (HP-β-CD: 
evodiamine  =  2:1, mole ratio), EVO/HP-β-CD com-
plexes, and HP-β-CD were accurately weighed (10  mg) 
and then placed into aluminium pans. The pans were 
sealed and heated from 30 to 300  °C at a scanning rate 
of 10 °C/min under a nitrogen flow of 20 mL/min with a 
blank aluminium pan as a reference.
Fourier transform infrared spectroscopy (FTIR)
FTIR spectra of evodiamine, the physical mixture, EVO/
HP-β-CD complexes, and HP-β-CD were recorded on a 
spectrophotometer (ALPHA, Bruker, Germany) in the 
wave number range of 4000–400/cm using KBr tablets.
X‑ray powder diffractometry (XRD)
Powder X-ray diffraction patterns of evodiamine, the 
physical mixture, EVO/HP-β-CD complexes, and 
HP-β-CD were recorded on a Rigaku D/MAX 2500  V 
diffractometer (Rigaku, Japan) with Ni-filtered Cu Ka 
radiation at a voltage of 40 kV and 100 mA current. The 
scanning rate was 8°/min over a 2θ range from 3 to 50°.
Ultraviolet spectroscopy (UV) absorption of evodiamine 
and its complexes with HP‑β‑CD
Evodiamine ethanol solutions (final concentration of 
2.95 ×  10−4 M) were added to different concentrations 
of HP-β-CD (0, 5, 10 and 20 %, w/v) and the combined 
solutions were treated with ultrasonic cleaner for 30 min 
at 298  K. Then, the effects of the HP-β-CD on the UV 
spectra of evodiamine were determined using a DU800 
visible–UV spectrophotometer (Beckman Coulter, USA) 
scanning from 200 to 600 nm.
NMR spectra and 2D 1H–1H rotating frame overhauser effect 
spectroscopy (2D ROESY)
1HNMR spectra for HP-β-CD, evodiamine, and EVO/
HP-β-CD complexes were recorded by an INOVA-
500 spectrometer (Varian, USA) at 298  K in denudated 
DMSO. A ROESY experiment was performed on a 
DRX500 spectrometer (Bruker Biospin, Rheinstetten, 
Germany) at 298 K in denudated DMSO. Samples were 
equilibrated for 24 h before measurement.
Determination of Pgp ATPase activity
The Pgp-Glo™ Assay Systems were used to verify 
whether EVO/HP-β-CD complexes or HP-β-CD could 
inhibit Pgp ATPase activity. Briefly, sodium orthovana-
date (Na3VO4), verapamil, or test compounds diluted 
in assay buffer were added to a 96-well white opaque 
plate, while the assay buffer was used as negative con-
trol. Then, 20 µL of diluted Pgp membranes and 10 µL of 
25 mM MgATP were also added to the wells. The plate 
was incubated at 37 °C for 40 min. Afterwards, the ATP 
remaining in the wells was detected as a luciferase-gen-
erated luminescent signal. Basal Pgp ATPase activity was 
determined as the difference between the ATP hydroly-
sis of the negative control and that of the Na3VO4 sam-
ple. Verapamil, a typical Pgp substrate, also served as a 
positive control.
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Cell viability assay
HepG2 cells were cultured in 96-well plates at a den-
sity of 1 ×  104 cells/well and incubated in a 37  °C, 5  % 
CO2 incubator for 24  h. Then, the cells were treated 
with various concentrations of the drugs and incubated 
for another 24 h. Ten microliters of MTT solution (final 
concentration of 0.5  mg/mL) was added to the culture 
medium, and the plates were incubated for 4 h at 37 °C. 
After aspirating the supernatants, 100 μL of DMSO was 
added to dissolve the formazan salts, and the absorb-
ance was measured at 490 nm on a Victor X5 plate reader 
(Perkin Elmer, USA).
Caspase assays
Cells were seeded at a density of 3  ×  106 cells/well in 
6-well plates for 24  h and treated with various concen-
trations of evodiamine, EVO/HP-β-CD complexes, or 
HP-β-CD for an additional 24 h. Then, the cells were har-
vested by trypsinization and centrifugation. After wash-
ing the cells twice with pre-cooled PBS (pH 7.4), ice-cold 
cell lysis buffer was added to the cells, which were then 
placed in an ice bath for 15  min to extract the protein. 
The caspase-3 and -8 activities were detected with cas-
pase colorimetric assay kits (Enzo Life Sciences, USA). 
Briefly, 20  µL of cell lysates, 70  µL of assay buffer, and 
10 µL of the Ac-DEVD-pNA or Ac-IETD-pNA substrates 
were added to 96-well plates, mixed, and incubated at 
37  °C overnight. After incubation, the absorbance was 
quantified at 405 nm on a Victor X5 plate reader.
Hoechst staining
Hoechst 33258 staining is usually used to analyse cell 
nuclear morphologies after apoptosis. The treated cells 
(as described in “Caspase assays” section) were fixed with 
4 % paraformaldehyde for 10 min in situ and then stained 
with Hoechst 33258 (5  μg/mL) for 3  min at room tem-
perature in the dark. After washing twice with PBS, the 
cells were observed on a LSM 710 laser scanning confo-
cal microscope (Carl Zeiss, Germany).
TUNEL assay
The TUNEL assay was used to confirm apoptosis induced 
by evodiamine, EVO/HP-β-CD complexes, and HP-β-CD 
according to the protocol of a commercial kit (Beyotime, 
China). Cells seeded in 6-well plates were fixed with 4 % 
paraformaldehyde for 30  min. After washing with PBS, 
the cells were permeabilized with 0.1 % Triton X-100 in an 
ice bath for 2 min. Next, the cells were treated with detec-
tion buffer, which included fluorescein-12-dUTP and 
DNA-terminal deoxynucleotidyl transferase, at 37  °C in 
a humid atmosphere in the dark for 1 h. Finally, the cells 
were observed and photos were taken with an ECLIPSE-
Ti inverted fluorescence microscope (Nikon, Japan).
Flow cytometry analysis
Cells were seeded in 6-well plates at a density of 9 × 105 
cells/well and cultured at 37  °C for 24 h. Then, the cells 
were treated with 1  µM evodiamine or EVO/HP-β-CD 
complexes for 26 or 28 h, respectively. The cells were then 
harvested with 0.25 % trypsin solution (w/v) and washed 
twice with pre-cooled PBS. Finally, the collected cells 
were treated according to the protocols of the Annexin 
V apoptosis detection kit (FITC) and analysed using an 
Accuri C6 flow cytometer (BD, USA).
Statistical analysis
One-way analysis of variance (one-way ANOVA) was 
used to test for significant differences using Origin 8.0 
software (MicroCal, USA). P values less than 0.05 were 
considered to be statistically significant. All of the results 
were expressed as the mean  ±  the standard deviation 
(SD).
Results and discussion
Results of phase solubility studies
Phase-solubility analysis is a traditional method for 
determining the influence of inclusion complex agents 
on a solubilized drug. The phase solubilities of evodi-
amine and HP-β-CD are shown in Fig. 2, and the curve 
is identified as AP-type (r2 =  0.9829), which is increas-
ing positively. According to Uekama et al. [23] this find-
ing indicates that more than one HP-β-CD molecule 
complexed with one guest molecule at higher HP-β-CD 
Fig. 2 Phase solubility diagram for evodiamine with HP‑β‑CD
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concentrations. As previously reported, drug/cyclodex-
trin complexes form aggregates or micelles in aqueous 
solutions and can further solubilize the drug through 
non-inclusion complexation [24, 25]. The solubility of 
evodiamine in water increased to 0.2  mmol/L (relative 
to 60.31  μg/mL) when the concentration of HP-β-CD 
was 350 mmol/L, which is approximately 158-fold higher 
than the intrinsic solubility in water (0.38 μg/mL, deter-
mined in this study).
DSC thermograms
The thermograms of evodiamine, the physical mixture of 
evodiamine and HP-β-CD, EVO/HP-β-CD complexes, 
and HP-β-CD are shown in Fig. 3A. The DSC curve given 
in Fig. 3A (a) shows a sharp endothermic peak for evo-
diamine at 293.15  °C (ΔH  =  128.75  J/g), which is the 
melting point of evodiamine. The HP-β-CD thermogram 
shown in Fig. 3A (d) exhibits a very broad endothermic 
peak near 80 °C due to the loss of water molecules from 
the cyclodextrin cavity at increasing temperatures. The 
physical mixture presented endothermic peaks of both 
evodiamine and HP-β-CD, as shown in Fig.  3A (b), but 
the melting point of evodiamine was shifted to a lower 
temperature (286.19 °C) due to interactions between evo-
diamine and HP-β-CD during the DSC scan. In contrast, 
the fusion peak of EVO/HP-β-CD did not exhibit the 
evodiamine endothermic peak, suggesting that the evo-
diamine crystal characteristic was lost and evodiamine 
inclusion complexes with HP-β-CD were formed.
FTIR spectra
The FTIR spectra of evodiamine, the physical mixture of 
evodiamine and HP-β-CD, EVO/HP-β-CD complexes, 
and HP-β-CD are shown in Fig.  3B. The evodiamine 
FTIR spectrum revealed intense absorption at 3219/cm, 
which is characteristic of –NH group absorption peaks. 
It also included cyclobenzene absorption peaks, which 
were observed at 1494, 1280 and 734/cm. The character-
istic peaks at 2943 and 2845/cm were attributed to –CH3 
and –CH2 groups, respectively. Another characteristic 
absorption peak at 1606/cm was for the carbonyl group. 
The strong absorption peak at 3403/cm is a character-
istic peak of the HP-β-CD hydroxyl group. The physical 
mixture spectrum had peaks that corresponded to both 
HP-β-CD and evodiamine (3403/cm for the hydroxyl 
group and 1606/cm for the carbonyl group) but no –NH 
group or cyclobenzene fingerprint peaks, which may be 
due to the formation of aggregates during kneading and 
tableting. Furthermore, the EVO/HP-β-CD FTIR spec-
trum showed characteristic peaks similar to those of 
HP-β-CD, which indicates that some of the evodiamine 
groups might be in the HP-β-CD cavity, suggesting for-
mation of the inclusion complexes.
XRD
XRD is another effective method for confirming the pres-
ence of drug/HP-β-CD inclusion complexes in powder or 
microcrystalline states. As shown in Fig. 3C, the free evo-
diamine powder XRD diffraction pattern exhibited sharp 
peaks, which is characteristic of the pure compound’s 
crystalline nature, while the XRD diffraction patterns 
of HP-β-CD confirmed its amorphous state. However, 
some weaker intensity evodiamine characteristic peaks 
were still detectable in the physical mixture, as shown in 
Fig.  3C (b). The EVO/HP-β-CD inclusion complex dif-
fractogram was similar to that of amorphous HP-β-CD; 
however, no characteristic evodiamine peak was found. 
The diffractogram of the inclusion complex not showing 
the crystalline states indicated the formation of the EVO/
HP-β-CD inclusion complexes.
UV spectra
UV spectra can provide powerful evidence of the forma-
tion of EVO/HP-β-CD complexes. Therefore, UV spec-
tra were used to confirm evodiamine complex formation 
with varying HP-β-CD concentrations in aqueous solu-
tion. As shown in Fig.  3D, evodiamine ethanol solution 
alone displayed the strongest absorption peak at 225 nm. 
With increasing HP-β-CD concentrations, the absorption 
intensity at 225  nm became weaker. These changes are 
consistent with some evodiamine chromophore groups 
entering the HP-β-CD cavity [17, 26].
1H NMR and 2D ROESY NMR
1H NMR was used to identify the formation of evodi-
amine inclusion complexes with HP-β-CD. DMSO-d6 
was chosen as the solvent because the reactive hydrogens 
(-NH) contained in EVO/HP-β-CD could be substituted 
by the deuterium atom of D2O and to accommodate sol-
ubility constraints. DMSO-d6 was also chosen as the sol-
vent for analysing the structure of EVO/HP-β-CD, which 
was soluble in water. The evodiamine 1H resonances 
(Fig.  4A) were assigned as follows: 1H NMR (500  MHz, 
DMSO-d6) δ11.07 (s, H-5), 7.79 (d, J  =  7.5  Hz, H-10), 
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7.47 (t, J = 6.5 Hz, H-4), 7.36 (d, J = 8.1 Hz, H-1), 7.10 
(t, J = 7.5 Hz, H-11), 7.05 (d, J = 8.2 Hz, H-13), 7.00 (t, 
J = 7.4 Hz, H-12), 6.96 (t, J = 7.5 Hz, H-2), 6.12 (s, H-8), 
2.87 (S, -CH3), 4.61, 3.34 (m, H-7), 3.19, and 2.84–2.72 
(m, H-6). The formation of EVO/HP-β-CD inclusion 
complexes was confirmed by shifts in some of the evodi-
amine proton resonances. As shown in Additional file 1: 
Table S1, evodiamine signals showed differential shifts 
from 2 ×  10−2 to 10−2 ppm. However, the combination 
of protons was different. Namely, the inclusion of evo-
diamine with HP-β-CD was probably formed by a weak 
molecular assembly, rather than chemical bonding.
The presence of nuclear over-hauser effect (NOE) cross-
peaks between protons from two species indicates spatial 
contacts within 0.4 nm [27]. A 2D ROESY NMR study was 
performed to obtain the more conformational informa-
tion for the EVO/HP-β-CD inclusion complexes. Cros-
speaks were observed between the H-4 and H-10 protons 
on the evodiamine benzene rings and the HP-β-CD H-3′ 
proton, as well as between the evodiamine H-8 proton and 
the HP-β-CD H-4′ proton. The simultaneous interaction 
with both internal and external HP-β-CD protons may 
be related to the polymeric structure of HP-β-CD. Com-
bined with the 1H NMR results above mentioned, all these 
results indicated that at least two moles of HP-β-CD inter-
acted with one mole of evodiamine (the evodiamine A ring 
was in one HP-β-CD cavity and the E ring was in another 
HP-β-CD cavity, as shown in Additional file 2: Figure S1).
Influence of evodiamine and EVO/HP‑β‑CD complexes 
on Pgp ATPase activity
As shown in Fig.  5, evodiamine alone stimulates basal 
Pgp ATPase activity and inhibits verapamil-stimulated 
Pgp ATPase activity, which indicates that evodiamine 
is a Pgp substrate and binds to the Pgp drug-binding 
site competitively. HP-β-CD and the EVO/HP-β-CD 
inclusion complexes significantly inhibited Pgp ATPase 
activity. Therefore, HP-β-CD could be used to not only 
improve the solubility of the anticancer drugs but also 
reduce drug resistance.
Inhibition of HepG2 cell proliferation by evodiamine 
and EVO/HP‑β‑CD complexes
MTT assay was used to investigate the effects of evodi-
amine, HP-β-CD and EVO/HP-β-CD on HepG2 cells 
Fig. 3 Spectra analysis. A DSC curves, B FTIR spectra, and C XRD 
patterns of a evodiamine, b the physical mixture of evodiamine and 
HP‑β‑CD, c EVO/HP‑β‑CD complexes, and d HP‑β‑CD. D UV spectra of 
evodiamine: (a) in the absence of HP‑β‑CD, (b) in 5 % HP‑β‑CD, (c) in 
10 % HP‑β‑CD, and (d) in 20 % HP‑β‑CD water solution
◂
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Fig. 4 A 1H NMR spectra. a HP‑β‑CD, b EVO/HP‑β‑CD inclusion complexes, and c evodiamine in DMSO‑d6 at 298 K. B ROESY spectrum of the EVO/
HP‑β‑CD inclusion complexes in DMSO‑d6
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proliferation inhibition (Fig. 6). The IC50 value of evodi-
amine and EVO/HP-β-CD on HepG2 cells was 8.516 and 
0.977 μM, respectively. To evaluate the anti-cancer effect, 
we chose 10, 1 and 0.1 μM for further study. Correspond-
ingly, the highest concentration of HP-β-CD was 1.3 mM. 
Results showed that evodiamine and EVO/HP-β-CD 
complexes significantly inhibited HepG2 cell viability 
in a concentration-dependent manner (P  <  0.01). How-
ever, 1.3  mM HP-β-CD had no effect on cell viability. 
Moreover, the inhibition of EVO/HP-β-CD complexes on 
HepG2 cells proliferation inhibition was better than that 
of free evodiamine, suggesting that HP-β-CD improves 
the cellular uptake efficacy [28].
Evodiamine and EVO/HP‑β‑CD complexes induce apoptosis 
by activating caspase‑3 in HepG2 cells
Apoptotic events are closely related to caspase activ-
ity, and caspase-3, which is located downstream of the 
caspase cascade, plays a predominant role in activating 
effect or caspases that lead to apoptosis. Therefore, cas-
pase-3 and -8 activities were determined by colorimet-
ric analyses. As shown in Fig. 7A, caspase-3 activities in 
HepG2 cells were enhanced in a concentration-depend-
ent manner after the cells were exposed to either evodi-
amine or EVO/HP-β-CD. Moreover, the EVO/HP-β-CD 
complexes could more effectively induce caspase-3 activ-
ity than equimolar concentrations of evodiamine alone. 
In contrast, HP-β-CD alone had no effect on caspase-3 
Fig. 5 Effects of evodiamine, EVO/HP‑β‑CD complexes, and HP‑β‑CD 
on Pgp ATPase activity. Values given are the mean ± SD (n = 3). 
#P < 0.05 and ##P < 0.01 significantly stimulated basal Pgp ATPase 
activity. *P < 0.05 and **P < 0.01 significantly inhibited basal Pgp 
ATPase activity
Fig. 6 Effects of evodiamine, EVO/HP‑β‑CD complexes, and HP‑β‑CD 
on HepG2 cell proliferation. A, B The non‑linear regression analyses 
were performed to estimate the half‑maximal inhibitory concentra‑
tions (IC50) of EVO/HP‑β‑CD and evodiamine. C Cell proliferation 
inhibition of presented concentrations of evodiamine, EVO/HP‑β‑CD 
(0.1–100 μM) and HP‑β‑CD (1.3 mM) was evaluated by MTT. Values 
given are the mean ± SD (n = 6). **indicates significant differences 
compared with the control group (P < 0.01). ##indicates significant dif‑
ferences between evodiamine and EVO/HP‑β‑CD complexes groups 
(P < 0.01)
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activity. It has been reported that evodiamine is a Pgp 
substrate; in contrast, HP-β-CD has been shown to be 
a Pgp inhibitor, suggesting that it could improve the 
absorption of Pgp substrates. Thus, the inclusion effect 
of HP-β-CD to enhance evodiamine solubility and inhibit 
Pgp could improve evodiamine cellular uptake. How-
ever, caspase-8 activities were not significantly altered 
by the same treatments (Fig. 7B). Therefore, caspase-3 is 
activated by evodiamine and EVO/HP-β-CD complexes 
to execute apoptosis, implying that caspase-3 is related 
to evodiamine and EVO/HP-β-CD complex-induced 
apoptosis.
HepG2 cell apoptosis induced by evodiamine and EVO/
HP‑β‑CD complexes
In general, apoptotic cells display some specific morpho-
logical and biochemical characteristics, including cell 
rounding and shrinkage, membrane blebbing, chromatin 
condensation [29], and mitochondrial inner membrane 
potential changes [30]. Hoechst 33258 is a cell-permeable 
nucleic acid stain that is very sensitive to DNA conforma-
tion and chromatin state. As shown in the photographs 
(Fig.  8A), morphological changes, such as chromatin 
condensation, were seen in the nuclei of the apoptotic 
cells induced by evodiamine and EVO/HP-β-CD. How-
ever, the karyomorphism of cells treated with HP-β-CD 
alone or with the vehicle was still very intact. The TUNEL 
assay was used to further confirm DNA fragmentation. As 
shown in Fig. 8B, positive signal was detected in HepG2 
cells treated with evodiamine or EVO/HP-β-CD com-
plexes. However, cells treated with HP-β-CD alone or 
with the vehicle do not exhibit cell-specific green fluores-
cence. These results showed that the apoptosis occurring 
in the HepG2 cells was induced by evodiamine or EVO/
HP-β-CD complexes.
Flow cytometry combined with Annexin V-FITC/PI 
staining was also applied to confirm that the apoptosis 
occurring in the HepG2 cells was induced by evodiamine 
or EVO/HP-β-CD complexes. As shown in Fig.  8C, evo-
diamine and EVO/HP-β-CD complexes could trigger 
apoptosis in HepG2 cells in a time-dependent manner. 
Furthermore, EVO/HP-β-CD complexes could more 
effectively induce HepG2 cells apoptosis than evodiamine 
alone.
Conclusions
The EVO/HP-β-CD inclusion complexes were pre-
pared successfully. The DSC, FTIR, XRD, UV, 1HNMR 
and 2D ROESY results all suggest the formation of 
EVO/HP-β-CD complexes. Additionally, the antitumor 
activities of the EVO/HP-β-CD complexes on HepG2 
cells were better than evodiamine alone, as confirmed 
by the MTT assay, caspase-3 assay, and two-colour 
analysis of FITC-AnnexinV/PI staining. This increase 
in antitumor activity can be attributed to the enhance-
ment of evodiamine solubility and the inhibition of 
Pgp ATPase activity by HP-β-CD, which improved 
evodiamine cellular uptake. Based on our results, 
Fig. 7 Effects of evodiamine, EVO/HP‑β‑CD complexes and HP‑β‑CD 
on caspases in HepG2 cells. Values of A caspase‑3 and B caspase‑8 
activities are reported as the mean ± SD (n=3). *Compared with 
control group, P < 0.05. **Compared with control group, P < 0.01. 
#Compared between evodiamine and EVO/HP‑β‑CD complexes 
groups, P < 0.05
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Fig. 8 Study of apoptosis with staining. A Morphology of HepG2 cells after Hoechst staining (200× magnifications). B Apoptotic cells induced by 
evodiamine or EVO/HP‑β‑CD complexes after TUNEL assay (100× magnification). C Apoptosis induced by 1 μM evodiamine or EVO/HP‑β‑CD com‑
plexes for 26 or 28 h, respectively, and detected by flow cytometry analysis after staining with Annexin V‑FITC/PI. The percentages in the upper–right 
and lower–right corners are the portions of late‑stage and early‑stage apoptosis, respectively
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EVO/HP-β-CD complexes are very promising for drug 
delivery to enhance the bioavailability of evodiamine 
in vivo.
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